financetom
Business
financetom
/
Business
/
Kits Eyecar Narrows Q4 Loss, Revenue Grows
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Kits Eyecar Narrows Q4 Loss, Revenue Grows
Mar 6, 2024 6:09 AM

08:50 AM EST, 03/06/2024 (MT Newswires) -- Kits Eyecare Ltd ( KTYCF ) . (KITS.TO), a vertically integrated eyecare provider, which saw its shares lose 3% yesterday, said Wednesday that it narrowed its fourth-quarter net loss to $491,000, or $0.02 per diluted share, from a loss of $1.4 million, or $0.04 per diluted share, a year earlier.

The improvement was mainly because of the higher revenue and gross profit, offset by a rise in foreign exchange loss during the period.

Revenue for the quarter ended Dec. 31, 2023, was $31.7 million, up from $26.2 million a year earlier. The company said the increase was mainly driven by "strong" repeat customer revenue in both contact lenses and eyeglasses, higher average order value, and a growth in repeat eyeglass customers.

Adjusted EBITDA for Q4 was $862,000 versus $441,000 a year ago. The improvement in adjusted EBITDA was primarily attributable to the increase in revenue and gross profit, offset by an increase in foreign exchange loss during the period, the company said.

On Dec. 31, 2023, the company reported cash and cash equivalents of $16 million, as compared with $18.8 million on Dec. 31, 2022.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
EyePoint's Phase 2 Trial of Duravyu to Treat Diabetic Macular Edema Meets Endpoints; Shares Still Slump Pre-Bell
EyePoint's Phase 2 Trial of Duravyu to Treat Diabetic Macular Edema Meets Endpoints; Shares Still Slump Pre-Bell
Feb 5, 2025
09:12 AM EST, 02/05/2025 (MT Newswires) -- EyePoint Pharmaceuticals ( EYPT ) reported six-month results from a phase 2 trial of Duravyu to treat diabetic macular edema that met primary and secondary endpoints, but its shares still slumped in premarket trading. The company said the trial demonstrated clinically meaningful outcomes, such as continued safety with no Duravyu-related ocular or systemic...
Feb 5, 2025
...
Equinor Unveils $5 Billion Buyback, Trims Renewables Spending As Oil & Gas Output Rises
Equinor Unveils $5 Billion Buyback, Trims Renewables Spending As Oil & Gas Output Rises
Feb 5, 2025
Equinor ASA ( EQNR ) shares are trading lower after the company reported fourth-quarter FY24 results. Revenue and other income fell 5% year-over-year (Y/Y) to $27.654 billion and adjusted revenue declined 7% Y/Y to $26.418 billion. The consensus estimate stood at $25.973 billion. Total equity liquids and gas production decreased 6% Y/Y to 2,072 mboe per day, with equity liquids production falling 6% Y/Y to 1,081 mboe per day...
Illinois Tool Works forecasts 2025 profit below estimates
Illinois Tool Works forecasts 2025 profit below estimates
Feb 5, 2025
Feb 5 (Reuters) - Illinois Tool Works ( ITW ) on Wednesday forecast annual profit below Wall Street expectations, as high borrowing rates and sticky inflation force customers to slow investments on industrial equipment. Shares of the company were down 3% before the bell. Higher borrowing costs have reduced corporate spending, muting the impact of steady demand from the automotive...
Copyright 2023-2026 - www.financetom.com All Rights Reserved